Lutetium, actinium or lead: Can isotope type offer an edge in radiotherapy?

Once considered a niche cancer therapy, radioligands are in the midst of a renaissance.

“If you think about where ADCs were four or five years ago, that’s roughly where radioligand therapies [RLT] are now,” Novartis’ head of radioligand therapies Jeevan Virk told Endpoints News in an interview. Novartis is one of the big names in the space, with the US approvals of Lutathera and Pluvicto in 2018 and 2022, respectively.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

CMS inpatient final rule will have muted impact on medtech companies, analysts say

Dive Brief: The Centers for Medicare and Medicaid Services’ Inpatient Prospective Payment System (IPPS) final rule will have limited impact on medtech companies, according to

August 3, 2023

Wearable tech reveals: Social constructs and physical activity shape global sleep patterns

Researchers analyze sleep data from wearable devices to assess sleep patterns. Societal factors influence sleep quality and quantity, with exercise playing a positive role. Understanding

June 20, 2023

Mediterranean diet may reduce type-2 diabetes risk in fatty liver patients

Researchers investigate how Mediterranean diet adherence reduces risk of type-2 diabetes in adults with metabolic dysfunction-associated fatty liver disease.

November 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.